Presentation is loading. Please wait.

Presentation is loading. Please wait.

Survival and tumor burden of mice bearing peritoneally disseminated gastric cancer. Survival and tumor burden of mice bearing peritoneally disseminated.

Published byBarry Wood Modified over 4 years ago

Similar presentations

Presentation on theme: "Survival and tumor burden of mice bearing peritoneally disseminated gastric cancer. Survival and tumor burden of mice bearing peritoneally disseminated."— Presentation transcript:

1 Survival and tumor burden of mice bearing peritoneally disseminated gastric cancer.
Survival and tumor burden of mice bearing peritoneally disseminated gastric cancer. MKN-28 cells were injected i.p. into severe combined immunodeficiency mice, and tumor was allowed to develop for 10 days. Mice were treated i.p. with CRAds or replication-deficient control virus and followed for survival. A, all oncolytic viruses significantly improved the survival of mice over mock (P < ) and Ad5luc1 (P < 0.05) injected mice. B, 50 days after injecting the cells, serum samples were collected from the tail vein to measure tumor marker βhCG. Lotta Kangasniemi et al. Clin Cancer Res 2006;12: ©2006 by American Association for Cancer Research

Download ppt "Survival and tumor burden of mice bearing peritoneally disseminated gastric cancer. Survival and tumor burden of mice bearing peritoneally disseminated."

Similar presentations

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.
Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.
H31m1-PDL1 cells form progressively growing tumors in WT mice.

H31m1-PDL1 cells form progressively growing tumors in WT mice.
Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.
Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.

Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.
Effect of MI-773 and/or cisplatin in a preclinical model of ACC

Effect of MI-773 and/or cisplatin in a preclinical model of ACC
Activity of MAC-321 (i. v. and p. o

Activity of MAC-321 (i. v. and p. o
Mouse lymphoma model. Mouse lymphoma model. A, EL-Arf−/− cells (1 × 106) were tail-vein injected into C57BL/6 mice. LNIWC imaging was separated into 2.

Mouse lymphoma model. Mouse lymphoma model. A, EL-Arf−/− cells (1 × 106) were tail-vein injected into C57BL/6 mice. LNIWC imaging was separated into 2.
Protection from 4T1 tumor rechallenge in treated mice.

Protection from 4T1 tumor rechallenge in treated mice.
Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.

Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.
Mice immunized twice with RRBC showed superior protection to tumor challenge with αGal-positive MC38 colon carcinoma cells compared with mock-immunized.

Mice immunized twice with RRBC showed superior protection to tumor challenge with αGal-positive MC38 colon carcinoma cells compared with mock-immunized.
In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s

In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s
Effect of HA on hematopoietic recovery in tumor-bearing mice.

Effect of HA on hematopoietic recovery in tumor-bearing mice.
GS87 demonstrates efficacy in a circulating AML mouse model system.

GS87 demonstrates efficacy in a circulating AML mouse model system.
coTCRcys-transduced T cells control tumor growth in vivo.

coTCRcys-transduced T cells control tumor growth in vivo.
A, Overall survival of patients treated with CAR T cells (black line; n = 15). A, Overall survival of patients treated with CAR T cells (black line; n.

A, Overall survival of patients treated with CAR T cells (black line; n = 15). A, Overall survival of patients treated with CAR T cells (black line; n.
EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. A,

EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. A,
SBC-5 miR-335+ xenografts abrogated completely, or in part, skeletal osteolytic lesions in humanized NOD/SCID IL2Rγnull immunodeficient mice. SBC-5 miR-335+

SBC-5 miR-335+ xenografts abrogated completely, or in part, skeletal osteolytic lesions in humanized NOD/SCID IL2Rγnull immunodeficient mice. SBC-5 miR-335+
Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c
Matriptase-2 inhibited breast tumor development in vivo.

Matriptase-2 inhibited breast tumor development in vivo.

Similar presentations

Ads by Google